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therewith is price elastic. We estimate that approximately 40% of the increase in pre-
scription volume results from REGO. Additionally to the increase in expenditures the 
sickness funds are facing a loss of income as less co-payment rates are paid. Prescrip-
tions with prices lower than the co-payment rate are not paid by the insured anymore, 
but by the sickness funds. These low-price prescriptions cause a dramatic increase in 
volume, however, not a decisive increase in total expenditures. CONCLUSIONS: The 
time courses allow us to evaluate the effects of REGO. Furthermore they reveal 
information about the behaviour of the demand function, when the price drops to 
zero. The intention of REGO is to improve equity by protecting poorer and heavy 
users of prescription drugs from the ﬁnancial burden of co-payments. Demand 
increases, when REGO reduces the price for prescription drugs to a 0. This could 
indicate an improvement in equity and access, however, affects on efﬁciency have to 
be shown in further analysis.
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OBJECTIVES: The distribution of free samples to patients in the US, the retail value 
of which is US$20 billion annually, is controversial. Proponents assert that free 
samples improve medication access for low-income patients while opponents argue 
free sample availability drives the choice of expensive, brand-name pharmaceuticals. 
It is critical to shed light on the beneﬁts and costs of free samples for older adults, in 
particular, given their high drug cost burden. Our objective was to determine the 
proportion of older adults receiving free samples, and to examine the association 
between free sample receipt and communication with physicians and cost-related 
non-adherence to medicines. METHODS: In 2006, we conducted a national telephone 
survey of persons age 65 and older in the U.S., over-sampling those with low-incomes. 
The survey included several questions related to prescription drug insurance coverage, 
medication use and doctor-patient communication. RESULTS: Half of older adults 
surveyed had received free samples from their doctors at least once in the past 12 
months, with 21% receiving samples more than once. Two thirds of seniors who had 
talked to their doctor about the cost of medicines they are taking received free samples 
compared to 43% of those who did not have such discussions. Seniors who received 
free samples were less likely to agree there is nothing their doctor can do to help lower 
drug costs (40% vs. 47%) than those who did not receive samples. Free sample receipt 
was associated with a lower risk of cost-related non-adherence (failing to ﬁll prescrip-
tions, skipping or reducing doses due to cost) (31% vs. 26%). CONCLUSIONS: 
Receipt of free samples is common among older adults and appears to increase with 
discussions of drug costs between doctors and patients. Free sample receipt may help 
reduce cost-related non-adherence, however, further study is needed to shed light on 
these behaviors.
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OBJECTIVES: Our aim was to estimate the hospitalization length of stay (LOS) and 
risk of death within hospitalization, associated with the occurrence of post-operative 
residual curarization (PORC) and adverse events (AE) possibly or probably related 
to neuromuscular blockade reversal agents (NMBRA) use. METHODS: Data was 
obtained from hospitalizations occurring in Portuguese public hospitals in 2007. Surgi-
cal procedures from (ICD-9-CM CSP codes): central nervous (01–05), endocrine 
(06–07), respiratory (30–34), cardiovascular (35–39), hematologic and lymphatic 
(40–41) and digestive (42–54) systems were selected due to their high potential for 
NMBRA use. According to clinical expertise and ICD-9 diagnosis classiﬁcation, AE 
and events PORC were grouped into the following outcomes: bronchospasm, dyspha-
gia or dyspepsia, cardiac dysrhythmias, tachycardia, hypertension, hypotension, xero-
stomia, nausea, vomiting or abdominal pain, central nervous system complications 
and allergic, psychological, respiratory, sensation and visual disturbances. Data con-
sisted of admission and discharge date, age, gender, primary and secondary diagnosis, 
primary and secondary surgical procedures. No data was available regarding the type 
of NMBRA used. Within hospital, risk of death was estimated with parametric sur-
vival (Weibull) regression models. LOS was estimated through negative binomial 
regression models. RESULTS: The analysis included 136,150 surgical procedures 
(55.0% female and mean(SD) age 54.2(18.9) years). Rates of AE and PORC were 
25.5% and 3.0%, respectively. Crude death rate was 2.8%. The risk of death was 1.3 
(95%CI: 1.2–1.4) times higher in patients with AE and 2.0 (95%CI: 1.9–2.2) times 
higher in patients with PORC, adjusted for other covariates. The mean LOS was 5.3 
days (30 days, n  130,254). LOS was signiﬁcantly increased both in patients with 
at least one AE (2.2 days, 95%CI: 2.1–2.4) or at least one PORC event (7.4 days, 
95%CI: 6.7–8.2). CONCLUSIONS: Post-operative residual curarization and adverse 
events possibly or probably related to neuromuscular blockade reversal agents use are 
associated with increased inpatient death and extended hospital length of stay.
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OBJECTIVES: The occupancy rate is a calculation to show the actual utilization of 
the inpatient health facility for a period. It is expressed as a percent. Our aim was to 
deﬁne occupancy rates between 2000 and 2008 in the Middle-European country, 
Hungary. Health care of its 10 million inhabitants was “secured” by 59.584 beds until 
31st March 2007 and by 43.943 beds afterwards. METHODS: To calculate the 
average occupancy rate for a typical one-year reporting period, two data items are 
needed. The “Inpatient Days of Care” and the “Bed Days Available”. Data were got 
from the National Health Insurance Fund Administration. To calculate occupancy 
rate the (Inpatient Days of Care / Bed Days Available) x 100 formula was used. 
RESULTS: The highest occupancy rate between 2000–2008 in Hungary was 76.3% 
in 2001. From that time the occupancy rate continuously decreased independently of 
the decrease of beds available. The ﬁgure reached 66.9% in 2007. In 2008 a slight 
increase could be seen (70.7%), which seemed not to be signiﬁcant, but in comparison 
to the decrease of beds (26%) at spring of 2007. Examining the gathered monthly 
data, it was realized that in February bed occupancy was the highest, 77.2%. Examin-
ing occupancy rate for calendar days, it got the highest ﬁgure on Thursday, 77%. In 
order to deﬁne how many beds are really needed, it has to be examined occupancy 
rate on every single calendar day. Evaluating the data it was observed that there were 
days when occupancy rate was higher than 91% but regularly reached 80%. CON-
CLUSIONS: On the basis of the above mentioned it can be proved that planning bed 
number, in addition to yearly average, the daily occupancy rate has to be considered, 
as stress on health care is highly ﬂuctuating due to unplanned, sudden cases.
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OBJECTIVES: Cost calculations show the importance of the utilisation of the capac-
ity. The aim of the study is to analyse the percentage of bed occupancy in the intensive 
care units in Hungary according to the Diagnosis related Groups (DRG) system. 
METHODS: Data were derived from the National Health Insurance Fund Administra-
tion (NHI). The bed occupancy rate of the ﬁrst eleven months of the year 2008 were 
analysed and compared to the mean of the Hungarian rate and to the means of two 
other recognized specialties. RESULTS: The number of beds was not ﬂuctuated 
throughout the examined eleven months. The bed capacity of the Hungarian hospitals 
was 48.6 beds per 10,000 people. 2.82% of the total hospitals beds, 1.37 beds per 
10,000 people, were in intensive care units. The departments of internal medicine had 
14.54% and the departments of surgery had 10.95% share in the Hungarian hospital 
beds. The percentage of occupancy of the intensive care units was 58.2%, of the 
departments of internal medicine was 75.63% and of the departments of surgery was 
65.29%. The total Hungarian hospitals occupancy ratio was 69.84%, more than 10% 
higher compared to the intensive units. CONCLUSIONS: Without the variable costs 
of the treatments, the outlay of an intensive care unit is remarkable. A better occu-
pancy of the intensive care units can increase the reimbursement for the hospitals or 
the decreases in the number of inpatient beds can be a cost-reduction strategy in the 
Hungarian Diagnosis-related Groups (DRG) ﬁnancing system.
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OBJECTIVES: The management of the large patient population chronically treated 
with oral anticoagulation therapy (OAT) poses organisational challenges that in Italy 
are traditionally approached with centralised procedures, relying on hospital-based 
clinics. However, the availability of near-patient testing devices for the monitoring of 
OAT effectiveness (INR measurement) allows for alternative or complementary man-
agement models (patient self-monitoring—PSM). PSM has been proven effective and 
safe, and could be attractive, especially in the perspective of the patient, whose life 
could be severely affected by the costs and times implied in the process of the OAT 
management. In order to assess PSM potential economic impact in Italy, there is a 
need for real-world economic and organisational data. This study was planned to 
investigate treatment patterns and to estimate the average costs borne by OAT patients 
in Italy. METHODS: A 19-item questionnaire, investigating the characteristics of the 
patient, his/her therapeutic regimens, the structures involved and the distances from 
home, the frequencies and the amount of time implied in the management of the OAT, 
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was developed and administered with the support of the main Italian OAT patients’ 
association. Returned questionnaires were checked for consistence and valid data were 
summarised. Travelling costs and earning losses were evaluated according to published 
prices. RESULTS: A total of 4722 valid questionnaires were returned from all over 
Italy. The prevalent OAT management model in this sample relies on hospital-based 
anticoagulation clinics. Patients incur signiﬁcant transportation, earning loss, and 
other out-of pocket costs at an estimated mean overall monthly cost of about a30. 
The distribution of costs in the population is wide, and depends mainly on monitoring 
frequency, home-clinic distance, and employment status. CONCLUSIONS: This study 
contributes to clarify the organisational models of the Italian OAT population and 
delivers data on patients’ costs that may be used when evaluating alternative manage-
ment options.
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OBJECTIVES: The Hellenic Society for Pharmacoecnomics and Outcomes Research 
(HELSPOR) assessed the effectiveness of recent policy reforms on controlling phar-
maceutical expenditure in Greece. METHODS: The latest available data on pharma-
ceutical expenditure in Greece derived from the National Statistical Service (NSS) were 
analyzed for the period of 2000–2007. RESULTS: Pricing and reimbursement systems 
implemented in Greece have been based on cost-containment rather than economic 
evaluation criteria. Cost containment policies introduced in the past (positive reim-
bursement list, pricing at the lowest EU price) had limited or no effect. In 2006, the 
reimbursement list was abolished and currently all marketed prescription medicines 
are reimbursed by Social Insurance. This, however, does not appear to be a sustainable 
system, as Insurance Funds exhibit signiﬁcant deﬁcits and hospitals incur enormous 
debts (in December 2008, hospital debt towards pharmaceutical companies was a2.66 
billion, exhibiting a remarkable increase within a year (38.3%)). Although two laws 
have been voted to introduce a reimbursement system that would replace the positive 
list, none has yet been implemented. The outcome of the past and current pharmaceuti-
cal policies in Greece has been the increase of pharmaceutical expenditure. Pharma-
ceutical expenditure rose to a 4.5 billion in 2007, accounting for 21.6% of total health 
care expenditure and 2% of GDP. Pharmaceutical expenditure increased over the 
period 2000–2007 at a mean annual growth rate (MAGR) of 13.4%, a rate higher 
than total health care expenditure (10.3%). CONCLUSIONS: Pharmaceutical policy 
reforms have increased expenses for Insurance Funds and hospitals. Implementation 
of economic evaluation criteria could be a start for rational decision making and cost 
containment in the pharmaceutical sector.
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OBJECTIVES: Despite the availability of Hungarian methodological guidelines the 
quality of economic evaluations submitted in pharmaceutical reimbursement dossiers 
are rather heterogeneous. The 10–12 point international critical appraisal checklists 
are not detailed enough to ﬁlter the problems occurring in Hungarian studies, therefore 
they are not widely used. As a consequence only small proportion of economic evalu-
ations are published in medical journals, which limits the development of health eco-
nomic skills and the broad utilisation of economic rationale in medical decision-making. 
The aim of our study was to develop a relevant Hungarian checklist for the critical 
appraisal of economic evaluations. METHODS: Fifty economic evaluations submitted 
for reimbursement of pharmaceuticals in 2007–8 were scrutinized by two independent 
reviewers to identify the most common methodological problems. Reviewers had no 
intention to revise previous reimbursement decisions. Based upon the assessment of 
10 studies, a draft checklist was developed. After assessing 25 reports, an extended 
workshop was settled to reconcile the opinion of reviewers and to improve the check-
list. The reviewers scrutinized the second 25 economic evaluations according to the 
checklist. The checklist was ﬁnalized at a second workshop. RESULTS: The ﬁnal 
checklist consists of 3–8 dichotomised questions in several major topics concerning 
comparator selection, effectiveness, costs, sensitivity analysis, methodological 
approach and interpretation of results. When the checklist is used for critical appraisal, 
reviewers may exclude non-relevant question items. CONCLUSIONS: Our checklist 
is based on current Hungarian practice. As the published checklist will be ofﬁcially 
used for the appraisal of economic evaluations in reimbursement dossiers, submitters 
can assure the quality of their economic evaluations and predict outcomes of the 
health technology assessment process. The transparent method of single technology 
assessment may improve the consistency of pharmaceutical reimbursement decisions 
and the utilization of economic evaluations in other ﬁelds of health care 
decision-making.
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OBJECTIVES: To determine whether there is a relationship between pharmaceutical 
consumption and health care results. This issue is of highest importance in the French 
political debate, France being one of the countries in Europe with the highest phar-
maceutical consumption and related expenses. METHODS: The levels of health care 
status of seven European countries (France, Denmark, Germany, Italy, Spain, Sweden 
and the UK) are compared through a range of indicators coming from sources (OECD, 
Eurostat, WHO) or scientiﬁc publications and systematically analyzed in comparison 
with health care and pharmaceutical expenses in each country. The analysis ﬁrst relies 
on global health care indicators such as life expectancy, life expectancy without dis-
ability and mortality rates by causes. A focus is then made on the two major causes 
of death in Europe: cancer and cardiovascular diseases. Analysis is conducted on 2004 
data. RESULTS: The highest life expectancy at 65, both for men and women, is posi-
tively correlated with the level of pharmaceutical consumption and expenses. Several 
studies (OMS) have suggested the high level of performance of the French health care 
system. The rather low level of life expectancy at birth for men is mostly the results 
of high mortality rates for external causes (suicides, injuries), independent from the 
health care system. Low mortality rates for cardiovascular diseases are associated with 
good management of risk factors through pharmaceutical treatments (hypolipidemic 
drugs). Regarding cancer, good results in terms of survival rates at ﬁve years are 
associated with a level of drug consumption high in value but more moderate in 
volume, this suggesting the use of innovating products. CONCLUSIONS: While it is 
not possible to demonstrate a ﬁrm cause-to-effect relationship between the relatively 
high investment in health care and the relatively better health care status in France 
compared with its European neighbours, a range of facts and ﬁgures do converge in 
support of this hypothesis.
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OBJECTIVES: The purpose of this study was to characterize the drugs in short supply 
in the American market on or before June 1, 2009 and to determine if certain char-
acteristics affect the duration of drug shortages. METHODS: We examined if the US 
Food and Drug Administration’s policy of identifying which drugs in short supply are 
“medically necessary” is effective in reducing the length of those shortages and if the 
market concentration (the number of manufacturers) of a drug is associated with the 
length of its shortage. Medical drug shortages create disruptions for buyers such as 
hospitals and pharmacies. They can affect public health, especially when the drug has 
few or no alternatives and can be considered medically necessary. We compiled pub-
licly-available data from the American Society of Health-Systems Pharmacists (ASHP) 
and the Food and Drug Administration (FDA) to determine the lengths of shortages, 
whether each drug had been deemed “medically necessary” by the FDA, and the 
number of active or defunct manufacturers for each drug. Using that data, we per-
formed statistical analyses to test two null hypotheses: 1) that there is no association 
between a drug in short supply being labeled “medically necessary” by the FDA and 
the length of its shortage; and 2) that there is no association between the number of 
manufacturers for a drug in short supply and the length of its shortage. RESULTS: 
We failed to reject our null hypotheses for both active shortages and resolved shortage 
drugs as listed by the ASHP on June 1, 2009. CONCLUSIONS: These results suggest 
that the FDA’s policy of determining which in-shortage drugs are “medically neces-
sary” did not reduce the duration of those shortages. The ﬁndings also indicate the 
number of manufacturers for a particular drug or device in short supply is not associ-
ated with the length of its shortage.
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OBJECTIVES: On the 1st of May 2004 Hungary—together with many European 
countries—joined to the European Union which resulted in several changes in the 
Hungarian legislation. In the coverage policy of pharmaceuticals, the Directive 89/105/
EEC of the Council of the European Communities on Transparency was implemented 
Hungary in order to provide regulation on decision on drug prices. The aim of our 
study is to calculate the average delay of decision-making on pharmaceutical reim-
bursement. METHODS: The data derive from the drug reimbursement database of 
the National Health Insurance Fund Administration (OEP) of Hungary covering the 
4 year period of 2005–2008. We calculated the delay as the time between the submis-
sion of application by the manufacturer and the ﬁrst day of reimbursement of drug. 
Our analysis covered drugs submitted within the frame of simpliﬁed procedure, drugs 
submitted in the normal procedure were omitted. RESULTS: Between 2005–2008 the 
total number of applications was 519, 440, 399, 377; while the average delay was 94, 
